NCT05858632

Immune Spatial Features of Guselkumab Cutaneous Response

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Detailed description

This is a one-arm, open-label study to examine the effect of Guselkumab . Guselkumab is a FDA-approved medication for the treatment of psoriasis. This study will examine how Guselkumab affects immune cells within scalp psoriasis lesions. Ten subjects with moderate to severe scalp psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with Guselkumab treatment response.

Conditions

• Psoriasis of Scalp

Interventions

Type	Name	Description
DRUG	Guselkumab	Guselkumab treatment for \~ 9 months

Timeline

• Start date: 2023-07-01
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2023-05-15
• Last updated: 2023-08-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study